RecruitingPhase 1NCT07217171
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EvolveImmune United, Inc
- Principal Investigator
- EvolveImmune Study TeamEvolveImmune United, Inc
- Intervention
- EVOLVE104(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (8)
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Yale University Cancer Center, New Haven, Connecticut, United States
- The Winship Cancer Institute Emory University, Atlanta, Georgia, United States
- START Midwest, Grand Rapids, Michigan, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
- SCRI, Nashville, Tennessee, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07217171 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- ENROLLING BY INVITATIONPHASE2NCT07312578Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaPeking University
See all trials for Squamous cell carcinoma of the esophagus →